Specsavers DIGITAL

Target: Specsavers Research date: 23 October 2026 Scope: Corporate group, enterprise technology suppliers, digital infrastructure, cybersecurity, patient-data processing, clinical AI, Israeli technology-sector relationships, state procurement and occupied-territory operations. Evidence period: Historical records through 23 October 2026.

Enterprise Technology Stack & Vendor Relationships

Corporate technology structure

Specsavers is a privately owned international optical and hearing-care business founded by Doug and Dame Mary Perkins, with John Perkins serving as chief executive; the company operates through a group structure involving centrally supported store partnerships.^{1, 2, 3}

The company’s Northern European corporate material identifies the Perkins family’s continuing involvement and identifies Louis Nielsen as part of the Specsavers group following its 2005 acquisition.⁴

Accenture and Microsoft - 2021

On 21 June 2021, Accenture announced a strategic agreement to modernise Specsavers’ legacy IT architecture, working with Microsoft on cloud infrastructure, intelligent automation, cybersecurity and systems consolidation.⁵

The agreement built on an existing supplier relationship and was intended to reduce technology incidents, strengthen security and improve operational resilience.⁵

A 2021 executive interview separately described Specsavers’ implementation of Microsoft Azure and Power BI to centralise customer-data analytics, reporting and predictive customer relationship management.⁶

Valtech - 2023

On 4 April 2023, Valtech announced an expanded international technology consultancy relationship with Specsavers, following earlier engagement in Northern Europe.⁷

The programme concerned customer-facing digital services, technology architecture, composable systems and improvements to online and in-store customer journeys.⁷

Valtech named Contentful and Algolia among the technology partnerships relevant to its approach; the announcement does not independently confirm that Specsavers had separately licensed or deployed each product.⁷

BJSS / CGI and Microsoft Azure - 2025 acquisition context

A CGI case study describes the modernisation of Specsavers’ Find & Book system, originally delivered by BJSS before CGI acquired that company in February 2025.⁸

The implementation uses Microsoft Azure, upgraded monitoring and observability, and Monetate for A/B testing of appointment-booking journeys.⁸

CGI reports that the platform supported more than 200,000 weekly bookings across approximately 1,200 stores and had been deployed across five international markets at the case-study stage.⁸

These reported volumes identify Find & Book as a substantial customer-facing operational system.⁸

Merkle, Google and Databricks - 2025-era programme

Merkle documents its implementation of a Specsavers analytics framework using Google Analytics 4, Google Dataform, Google BigQuery and Databricks.⁹

The case study describes a multi-market data-engineering environment, automated schema handling and transformation of web analytics into governed datasets.⁹

Merkle reports a 90% reduction in query volume for a UK appointment-availability report and a reduction in Databricks ingestion time from approximately four hours to five minutes.⁹

Splunk, Somerford and ServiceNow - 2019–2025

Somerford Associates reports that it began supporting Specsavers’ Splunk programme in summer 2019, initially through an IT Service Intelligence proof of value.¹⁰

The relationship subsequently covered Splunk ITSI, Enterprise Security, Observability, log aggregation, security monitoring, infrastructure telemetry and operational incident management.¹⁰

Somerford describes deployment across Specsavers’ retail estate, corporate IT systems and supply-chain infrastructure, including incident-management integration with ServiceNow.¹⁰

Somerford’s published material references historical monitoring tools including Datadog, AppDynamics, SolarWinds and a product named Nimbus; this reference concerns enterprise monitoring and does not establish any relationship to the Israeli government Project Nimbus programme.¹⁰

A March 2023 recorded customer discussion involving Specsavers representative Graham Dawes corroborates the Splunk deployment and consolidation of monitoring platforms.¹¹

In December 2025, Specsavers’ Andy Slater discussed consolidation of more than 20 monitoring tools into the Splunk environment, confirming continuing use after November 2024.¹²

Oracle and Spinnaker Support - 2024

On 8 November 2024, Computer Weekly reported that Specsavers had replaced Oracle’s direct enterprise support arrangements with third-party support from Spinnaker Support for relevant Oracle systems.¹³

Spinnaker’s customer case study corroborates the relationship and describes a programme aimed at improving maintenance responsiveness, security support and the resilience of business-critical operations.¹⁴

Fujitsu - historical procurement [pre-2020]

A 2017 Computing report documents a £17.6 million Fujitsu digital transformation engagement covering 1,179 Specsavers stores in the UK and Europe.¹⁵

An earlier 2008 IT Pro report documents a global store IT infrastructure framework involving Fujitsu Siemens, including deployment, equipment servicing and central management arrangements.¹⁶

Both arrangements are historical [pre-2020] evidence; continuation of the original contracts into 2026 is unknown.^{15, 16}

Training and operational analytics - 2024–2026

DataCamp documents a Specsavers analytics-skills programme involving Power BI, Databricks, Python and SQL, with more than 115 learners participating.¹⁷

Cascader - clinical AI partnership, 2026

On 1 March 2026, Specsavers announced a partnership with medical AI company Cascader during the 100% Optical exhibition in London.^{18, 19}

Specsavers’ corporate announcement identifies the partnership’s purpose as exploring how artificial intelligence could support clinical practitioners, improve disease detection and help deliver improved patient outcomes.¹⁸

Independent healthcare technology reporting confirmed the announcement on 2 March 2026, followed by Optometry Today’s detailed report on 4 March 2026.^{20, 19}

The partnership specifically concerns prospective clinical decision-support technology rather than the enterprise cloud and cybersecurity modernisation covered by Specsavers’ other technology programmes.^{18, 21}

The published descriptions concern investigation and prospective implementation; they do not establish completed deployment across the Specsavers store network.^{19, 21}

Israeli-origin enterprise technology

No public evidence identified of a confirmed Specsavers licence, subscription, procurement or deployment involving Check Point, Wiz, CyberArk, SentinelOne, NICE, Verint, Claroty, Palo Alto Networks or comparable Israeli-origin cybersecurity vendors.

No public evidence identified that any confirmed systems integrator deployed Israeli-origin software into Specsavers’ environment as part of the documented programmes.

No public evidence identified establishing Israeli jurisdiction over the named Specsavers enterprise systems.

No public evidence identified establishing that Cascader is an Israeli-domiciled company or that its Specsavers partnership involves an Israeli technology vendor; the available registry record identifies Cascader Ltd as a UK company.²²

Surveillance, Biometrics & Retail Technology

Customer analytics and monitoring - 2021–2025

Specsavers’ 2021 executive interview documents predictive customer relationship management analysis using its Microsoft Azure and Power BI environment.⁶

The programme concerned commercial customer engagement, communications and appointment behaviour.⁶

The CGI/BJSS Find & Book programme includes Monetate A/B testing, analytics and observability to measure customer engagement and appointment-booking conversion.⁸

Merkle’s programme processes GA4 web analytics data through Google and Databricks technologies to support operational and marketing analysis.⁹

Infrastructure and security monitoring - 2019–2025

Somerford documents Specsavers’ use of Splunk products to monitor application performance, infrastructure health, security events and operational incidents across corporate and retail systems.¹⁰

The December 2025 Somerford interview confirms continued development of operational observability and automation capabilities.¹²

Clinical image analysis - 2026

Specsavers’ March 2026 Cascader partnership involves investigation of medical AI using information from optometry consultations, clinical images and associated data.^{18, 19}

Cascader describes its technology as supporting interpretation of ophthalmic imaging, including retinal optical coherence tomography, and clinical assessment of eye disease.²³

The company’s declared objectives include earlier disease detection and clinical decision support.²³

The partnership announcements do not establish deployment of facial identity recognition, gait identification or law-enforcement biometric systems.^{18, 19}

Facial recognition and biometric identification

No public evidence identified of Specsavers deploying Israeli-origin facial recognition, gait recognition, behavioural identification or automated identity-surveillance products from Trigo, BriefCam, Oosto/AnyVision, Trax or comparable vendors.

No public evidence identified connecting Specsavers’ consumer-facing virtual eyewear technology to Israeli-origin biometric surveillance vendors.

Predictive policing and workforce surveillance

No public evidence identified of Specsavers using Israeli-origin predictive-policing technology, military intelligence analytics, social-media surveillance or workforce-monitoring platforms.

Third-party and bundled deployment

No public evidence identified demonstrating that Israeli-origin biometric, retail surveillance or intelligence technology reaches Specsavers through its named systems integrators, cloud suppliers or enterprise software providers.

No public evidence identified of an Israeli-origin biometric or surveillance technology component within the documented Cascader partnership.

Cloud Infrastructure, Data Residency & Sovereign Cloud Participation

Microsoft Azure - 2021 onward

Accenture’s June 2021 strategic agreement included modernisation of Specsavers’ cloud infrastructure and related enterprise security capabilities with Microsoft.⁵

Specsavers executives separately described a Microsoft Azure data platform supporting centralised analytics and customer relationship management in 2021.⁶

CGI’s published Find & Book case study confirms Azure deployment for customer-facing booking infrastructure.⁸

Amazon Web Services - historical architecture

Everthere’s Specsavers case study documents an Australian prescription-glasses e-commerce system that securely transferred prescription information from an on-premises Melbourne data centre into AWS-hosted services.²⁴

The case study also describes involvement in online booking technology and preliminary planning for Microsoft Azure migration; its original implementation date and current production status are not established.²⁴

Google data infrastructure - 2025-era programme

Merkle identifies Google Analytics 4, BigQuery and Dataform as components of Specsavers’ enterprise analytics architecture, with downstream ingestion into Databricks.⁹

The documented system supports analytics across multiple markets, but the supplier does not identify an Israeli hosting region for Specsavers’ data.⁹

Clinical data processing and NHS systems - 2025–2026

NHS Data Security and Protection Toolkit records show that the Specsavers Optical Group headquarters recorded a standards-met publication for the 2025–26 reporting year on 23 June 2026.²⁵

A separate NHS record documents a standards-met 2025–26 headquarters publication for Specsavers Hearcare Group on 24 June 2026.²⁶

These records concern NHS data-security assessment status and do not identify the physical locations of all underlying commercial cloud workloads.^{25, 26}

Cascader clinical AI and patient-data exposure - 2026

The Specsavers-Cascader partnership concerns prospective clinical decision support based on ophthalmic examinations, images and clinical information.^{18, 21}

Cascader describes AI products that interpret retinal OCT images to help clinicians make evidence-based clinical decisions.²³

The partnership’s public announcements establish the proposed processing function but do not identify a production cloud provider, hosting region or patient-data transfer arrangement.^{18, 19, 21}

Cascader Ltd is registered in England and incorporated on 22 April 2025.²²

No public evidence identified establishing that Specsavers patient records or ophthalmic images have been transferred to Cascader as part of an operational deployment.

No public evidence identified establishing an Israeli processing location, Israeli-domiciled clinical-data subprocessor or Israeli legal access to patient information through the Cascader partnership.

Israeli infrastructure and sovereign cloud

No public evidence identified that Specsavers operates or leases a data centre in Israel.

No public evidence identified of Specsavers participation in Project Nimbus or another Israeli state cloud procurement programme.

No public evidence identified of a Specsavers contract supplying cloud hosting, data residency, digital sovereignty, cybersecurity or infrastructure-resilience services to Israeli government, intelligence or military institutions.

Data-exposure principle

The historically documented Australian architecture involved processing customer prescription data between a Melbourne data centre and AWS-hosted infrastructure, although the supplier does not specify the destination AWS region.²⁴

The documented Microsoft and Google relationships confirm use of global cloud technologies but do not establish that Specsavers information is processed, stored or legally accessible within Israeli jurisdiction.^{5, 8, 9}

The Cascader partnership introduces a documented 2026 clinical AI research and development relationship involving potential medical-image interpretation, but the public sources do not establish the jurisdiction of any operational processing environment.^{18, 21, 23}

No public evidence identified establishing an Israeli-controlled cloud tenancy, Israeli-domiciled clinical-data subprocessor or transfer of Specsavers customer data to Israeli state institutions.

Defence, Intelligence & Security Sector Technology Relationships

Military and intelligence contracts

No public evidence identified of a contract between Specsavers or its documented group businesses and the Israeli Ministry of Defence, Israel Defence Forces, military intelligence agencies or Israeli state security organisations.

Technology provision to security agencies

The verified Specsavers technology programmes concern retail systems, healthcare services, enterprise operations, customer booking, analytics and internal cybersecurity.^{5, 8, 9, 10}

The 2026 Cascader partnership concerns prospective medical AI decision support for community optometry and referral pathways.^{18, 19, 21}

No public evidence identified of Specsavers supplying these systems to Israeli military, intelligence or security agencies.

Dual-use technology

Specsavers’ documented technology environment includes cloud computing, enterprise cybersecurity monitoring, analytics and customer information processing.^{5, 9, 10}

Cascader’s stated medical AI applications concern clinical imaging, disease detection and diagnostic support.²³

No public evidence identified of those technologies being supplied by Specsavers for military surveillance, intelligence collection or security operations in Israel or occupied territories.

Offensive cyber and digital weapons

No public evidence identified of Specsavers developing, licensing, supplying or maintaining offensive cyber weapons, exploit platforms, digital targeting systems or military surveillance software.

Settlement operations

No public evidence identified of Specsavers or an identified franchise or subsidiary supplying a Specsavers-branded digital platform specifically to Israeli settlements in the West Bank, East Jerusalem or occupied Syrian Golan.

No public evidence identified linking the Cascader partnership to clinical technology provision within those territories.

AI, Algorithmic & Autonomous Systems

Commercial predictive analytics - 2021

A 2021 Specsavers executive interview described predictive modelling within customer relationship management, supported by a Microsoft Azure and Power BI data platform.⁶

The stated commercial purpose was improved customer communication, appointment management and business analytics.⁶

Data engineering and automation - 2025

Merkle’s documented Specsavers project uses automated data transformations, standardised schemas and analytics processing through Google Dataform, BigQuery and Databricks.⁹

The work concerned internal business intelligence and data-engineering efficiency.⁹

Operational automation - 2025

In December 2025, a Somerford podcast with Specsavers’ Andy Slater described continued development of observability, automation and interest in AIOps and OpenTelemetry.¹²

The discussion describes operational technology interests and does not establish deployment of a specific generative AI or autonomous decision-making system.¹²

Clinical AI partnership with Cascader - March 2026

Specsavers and Cascader announced a formal partnership on 1 March 2026 at the 100% Optical exhibition.^{18, 19}

Specsavers described the collaboration as an effort to investigate deployment of AI technology supporting clinicians, early disease detection, screening and improved patient outcomes.¹⁸

Cascader CEO Peter Thomas identified applications involving ophthalmic consultations, images, patient information and systemic-health insights.^{18, 19}

The collaboration builds on clinical AI research associated with Moorfields Eye Hospital and University College London’s Institute of Ophthalmology.^{18, 23}

Cascader’s declared technology focus includes artificial intelligence applied to retinal OCT imaging, clinical decision support and oculomics.²³

Clinical referral decision support - May 2026

In a follow-up interview published on 15 May 2026, Cascader optometry consultant Mike Horler described the proposed initial application as providing clinicians with diagnostic guidance and referral recommendations.²¹

The proposed workflow allows a clinician to enter or review patient information, obtain AI-supported estimates of possible conditions and consider recommended referral pathways.²¹

Horler emphasised that clinical responsibility and the final decision remain with the practitioner.²¹

Specsavers clinical services director Giles Edmonds described the partnership as an opportunity to investigate more effective clinical pathways and potential deployment at scale.²¹

The May 2026 interviews provide evidence of continuing development discussions after the March announcement but do not establish completed production deployment.²¹

Clinical applications under investigation

The announced partnership identifies glaucoma as a potential application for AI-supported referral management.^{19, 21}

Cascader’s broader technical programme includes analysis of retinal images and the identification of disease patterns through ophthalmic imaging.²³

The company also describes oculomics as a possible means of detecting systemic medical conditions through eye-related information.²³

The public partnership disclosures do not establish that every proposed application was implemented at Specsavers by October 2026.^{18, 21}

AI research data

HTN Health Tech News reported on 2 March 2026 that Moorfields maintained an ophthalmic research platform known as INSIGHT containing approximately 35 million images and related information.²⁰

The article discusses that research infrastructure separately from the Specsavers partnership and does not establish that Specsavers supplied patient data to INSIGHT or acquired unrestricted access to its contents.²⁰

No public evidence identified establishing that Specsavers’ clinical AI partnership uses Israeli surveillance datasets, intercepted communications or intelligence-derived information.

AI provision to Israeli state institutions

No public evidence identified of Specsavers developing, selling, licensing or providing artificial intelligence or machine-learning platforms to Israeli state, military or intelligence organisations.

No public evidence identified connecting Cascader’s documented Specsavers engagement to Israeli government AI procurement.

Autonomous targeting and weapons systems

No public evidence identified of Specsavers supplying autonomous targeting, fire-control, weapons-control or military target-generation systems.

No public evidence identified of Specsavers producing technology whose primary designed output is kinetic military targeting or weapons effects.

Technology Ecosystem & R&D Footprint

Corporate leadership and ownership - 2025–2026

Specsavers was founded by Doug and Dame Mary Perkins; their son John Perkins serves as chief executive.^{1, 2, 3}

A January 2026 Association of British Dispensing Opticians report identifies Doug Perkins as company chairman and confirms the group’s continuing family involvement.³

Independent reporting also describes Specsavers’ placement into a family trust to preserve long-term family ownership.³

The October 2026 Guernsey Press report identifies Doug and Mary Perkins as active founders and documents the group’s joint-venture ownership structure.²

Cascader clinical AI development relationship - 2026

The March 2026 partnership establishes an external clinical AI development relationship between Specsavers and Cascader.^{18, 19}

Cascader identifies Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology and Topcon Healthcare as organisations involved in its founding and development.²³

Cascader’s website identifies Dr Peter Thomas as chief executive and Professor Pearse Keane as chief medical adviser.²³

Cascader Ltd is an active UK-registered private company incorporated on 22 April 2025, with registered office in London.²²

The partnership concerns adaptation and potential deployment of clinically useful AI technologies in community eye-care settings.^{18, 21}

No public evidence identified establishing that Specsavers acquired Cascader or purchased a controlling equity interest in the company.

Israeli R&D centres

No public evidence identified of Specsavers operating an engineering office, technology R&D centre, accelerator, innovation laboratory or dedicated software-development facility in Israel.

No public evidence identified establishing that the Cascader collaboration includes an Israeli R&D centre.

Technology acquisitions and investments

No public evidence identified of Specsavers acquiring an Israeli cybersecurity, software, AI, surveillance or military technology company.

No public evidence identified of a Specsavers investment in an Israeli technology venture fund or startup.

No public evidence identified of Doug Perkins, Mary Perkins, John Perkins or the identified family ownership structure holding a documented controlling investment in an Israeli military technology, cyber-intelligence or surveillance company.

Group and subsidiary attribution

Corporate history identifies Louis Nielsen as a member of the Specsavers group following its acquisition in 2005, while independent corporate reporting identifies Newmedica as part of the wider Specsavers business.^{4, 3}

No public evidence identified of an Israeli surveillance, cybersecurity, defence-technology or state-cloud procurement relationship involving either of these named group businesses.

Patents and intellectual property

No public evidence identified of a significant Specsavers patent-licensing agreement, jointly owned technology patent or commercial software-development arrangement with Technion, Hebrew University, Weizmann Institute or another Israeli research institution.

No public evidence identified of Israeli institutional participation in the documented Specsavers-Cascader clinical AI collaboration.

Clinical and retail innovation

Specsavers’ documented innovation activity includes its international appointment-booking platform, prescription e-commerce architecture and enterprise analytics programmes.^{8, 24, 9}

The March 2026 Cascader partnership adds a documented clinical AI collaboration concerning disease detection, medical-image interpretation and clinical referral support.^{18, 19, 21}

No public evidence identified connecting those initiatives to an Israeli technology development facility or Israeli state-funded R&D programme.

Civil Society Scrutiny & Regulatory History

UN business and human rights reporting - 2026

The Business & Human Rights Resource Centre published information about the 25 September 2026 OHCHR update to the settlement-business database, reporting 214 companies from 11 countries and citing UN report A/HRC/63/20.²⁷

No public evidence identified establishing that Specsavers or an identified group entity appears in that database.

Specialist investigations

No public evidence identified of a Specsavers-specific technology investigation by Who Profits, AFSC Investigate, Amnesty International, Human Rights Watch, Citizen Lab, Access Now, B’Tselem, Al-Haq or SOMO concerning Israeli surveillance, military technology or occupied-territory digital infrastructure.

Boycott and divestment activity

No public evidence identified of an organised boycott or divestment campaign specifically directed at Specsavers’ technology provision to Israeli state institutions or settlements.

No documented Specsavers corporate response to such a technology-specific campaign was identified.

Regulatory and legal actions

No public evidence identified of an export-control investigation, sanctions proceeding, regulatory enforcement action or legal challenge concerning Specsavers’ provision of digital technologies to Israeli state, military or intelligence customers.

No public evidence identified of a regulatory proceeding connecting the Specsavers-Cascader partnership to Israeli state technology provision.

UK healthcare data-security oversight - 2026

NHS Data Security and Protection Toolkit records document standards-met publications for Specsavers Optical Group and Specsavers Hearcare Group in June 2026.^{25, 26}

These published records establish a reporting status for NHS data-security requirements; they do not constitute a finding about Israeli technology relationships.^{25, 26}

Clinical AI professional scrutiny - 2026

The Association of Optometrists reported the Specsavers-Cascader partnership on 4 March 2026 and published a further interview concerning implementation, professional judgement and clinical decision support on 15 May 2026.^{19, 21}

The follow-up reporting records discussion of the need for appropriate deployment, practical clinical integration and retention of clinician responsibility for referral decisions.²¹

The available reporting does not establish an Israeli government or settlement-related application of the partnership.^{19, 21}

Post-July 2024 and post-November 2024 technology activity

The Oracle support transition was publicly reported on 8 November 2024.¹³

Somerford’s December 2025 interview documents continuing Specsavers investment in Splunk-based operational monitoring after both dates.¹²

Specsavers announced its Cascader clinical AI partnership on 1 March 2026, and further professional reporting discussed implementation objectives in May 2026.^{18, 21}

No public evidence identified linking these post-2024 technology activities to Israeli state institutions, military technology procurement or occupied-territory digital infrastructure.